Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome.
CRISPR/Cas9
T lymphocytes
adoptive immunotherapy
checkpoint inhibitory molecule
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Mar 2022
16 Mar 2022
Historique:
received:
12
01
2022
revised:
11
03
2022
accepted:
14
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) represented a step forward in improving the outcome of patients with various refractory solid tumors and several therapeutic regimens incorporating ICI have already been approved for a variety of tumor entities. However, besides remarkable long-term responses, checkpoint inhibition can trigger severe immune-related adverse events in some patients. In order to improve safety of ICI as well as T cell therapy, we tested the feasibility of combining T cell-based immunotherapy with genetic disruption of checkpoint molecule expression. Therefore, we generated H-Y and ovalbumin antigen-specific CD8
Identifiants
pubmed: 35328630
pii: ijms23063207
doi: 10.3390/ijms23063207
pmc: PMC8955581
pii:
doi:
Substances chimiques
Hepatitis A Virus Cellular Receptor 2
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Berlin Institute of Health at Charité - Universitätsmedizin Berlin
ID : Johanna Quandt funding
Références
Cancer Res. 2011 May 15;71(10):3540-51
pubmed: 21430066
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Front Med. 2017 Dec;11(4):554-562
pubmed: 28625015
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Int J Mol Sci. 2020 Apr 05;21(7):
pubmed: 32260578
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Int J Cancer. 2021 Jun 15;148(12):3097-3110
pubmed: 33600609
Nat Immunol. 2002 Sep;3(9):844-51
pubmed: 12172545
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
Nucleic Acids Res. 2014 Dec 16;42(22):e168
pubmed: 25300484
Eur J Immunol. 2017 Feb;47(2):385-393
pubmed: 27873300
Biomed Pharmacother. 2020 Jan;121:109625
pubmed: 31733578
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Front Immunol. 2019 Dec 17;10:2965
pubmed: 31921205
Cancer Med. 2021 Jan;10(2):454-461
pubmed: 33249761
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cell. 1994 Jan 14;76(1):17-27
pubmed: 8287475
Cancer Discov. 2021 Jun;11(6):1368-1397
pubmed: 33811048
Cell Res. 2020 Apr;30(4):285-299
pubmed: 31974523
Lab Anim (NY). 2013 Jun;42(6):217-24
pubmed: 23689461
Semin Immunol. 2019 Apr;42:101305
pubmed: 31604537
Int J Mol Sci. 2020 Jul 15;21(14):
pubmed: 32679922
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
Oncoimmunology. 2016 Dec 23;6(1):e1261779
pubmed: 28197389
Clin Transl Med. 2021 Mar;11(3):e365
pubmed: 33784013
Nat Commun. 2019 Sep 11;10(1):4109
pubmed: 31511513
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
J Exp Med. 2011 Feb 14;208(2):395-407
pubmed: 21300912
Drug Des Devel Ther. 2020 Sep 08;14:3625-3649
pubmed: 32982171
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
Dev Biol. 2019 Jan 15;445(2):156-162
pubmed: 30359560
J Exp Med. 2010 Sep 27;207(10):2175-86
pubmed: 20819923
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374804
Cancer Gene Ther. 2020 Aug;27(7-8):528-538
pubmed: 31822814
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
J Exp Med. 2008 Nov 24;205(12):2699-701
pubmed: 19015312
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Dev Biol. 2014 Sep 1;393(1):3-9
pubmed: 24984260
Nature. 2018 Jul;559(7714):405-409
pubmed: 29995861
J Hematol Oncol. 2020 May 18;13(1):54
pubmed: 32423475
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Int J Mol Sci. 2017 Mar 16;18(3):
pubmed: 28300768
Transl Oncol. 2020 Mar;13(3):100738
pubmed: 32114384
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810